TY - JOUR
T1 - Volumetry based biomarker speed of growth
T2 - Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients
AU - Wennmann, Markus
AU - Kintzelé, Laurent
AU - Piraud, Marie
AU - Menze, Bjoern H.
AU - Hielscher, Thomas
AU - Hofmanninger, Johannes
AU - Wagner, Barbara
AU - Kauczor, Hans Ulrich
AU - Merz, Maximilian
AU - Hillengass, Jens
AU - Langs, Georg
AU - Weber, Marc André
N1 - Publisher Copyright:
© Wennmann et al.
PY - 2018/5/18
Y1 - 2018/5/18
N2 - The purpose of this study was to improve risk stratification of smoldering multiple myeloma patients, introducing new 3D-volumetry based imaging biomarkers derived from whole-body MRI. Two-hundred twenty whole-body MRIs from 63 patients with smoldering multiple myeloma were retrospectively analyzed and all focal lesions > 5mm were manually segmented for volume quantification. The imaging biomarkers total tumor volume, speed of growth (development of the total tumor volume over time), number of focal lesions, development of the number of focal lesions over time and the recent imaging biomarker ' > 1 focal lesion' of the International Myeloma Working Group were compared, taking 2-year progression rate, sensitivity and false positive rate into account. Speed of growth, using a cutoff of 114mm3/month, was able to isolate a highrisk group with a 2-year progression rate of 82.5%. Additionally, it showed by far the highest sensitivity in this study and in comparison to other biomarkers in the literature, detecting 63.2% of patients who progress within 2 years. Furthermore, its false positive rate (8.7%) was much lower compared to the recent imaging biomarker ' > 1 focal lesion' of the International Myeloma Working Group. Therefore, speed of growth is the preferable imaging biomarker for risk stratification of smoldering multiple myeloma patients.
AB - The purpose of this study was to improve risk stratification of smoldering multiple myeloma patients, introducing new 3D-volumetry based imaging biomarkers derived from whole-body MRI. Two-hundred twenty whole-body MRIs from 63 patients with smoldering multiple myeloma were retrospectively analyzed and all focal lesions > 5mm were manually segmented for volume quantification. The imaging biomarkers total tumor volume, speed of growth (development of the total tumor volume over time), number of focal lesions, development of the number of focal lesions over time and the recent imaging biomarker ' > 1 focal lesion' of the International Myeloma Working Group were compared, taking 2-year progression rate, sensitivity and false positive rate into account. Speed of growth, using a cutoff of 114mm3/month, was able to isolate a highrisk group with a 2-year progression rate of 82.5%. Additionally, it showed by far the highest sensitivity in this study and in comparison to other biomarkers in the literature, detecting 63.2% of patients who progress within 2 years. Furthermore, its false positive rate (8.7%) was much lower compared to the recent imaging biomarker ' > 1 focal lesion' of the International Myeloma Working Group. Therefore, speed of growth is the preferable imaging biomarker for risk stratification of smoldering multiple myeloma patients.
KW - Biomarker
KW - Risk stratification
KW - Smoldering multiple myeloma
KW - Speed of growth
KW - Volumetry
UR - http://www.scopus.com/inward/record.url?scp=85047198475&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.25402
DO - 10.18632/oncotarget.25402
M3 - Article
AN - SCOPUS:85047198475
SN - 1949-2553
VL - 9
SP - 25254
EP - 25264
JO - Oncotarget
JF - Oncotarget
IS - 38
ER -